Multicenter Targeted Population Screening of Late Onset Pompe Disease in Unspecified Myopathy Patients in Korea
- Author:
Jung Hwan LEE
1
;
Jin-Hong SHIN
;
Dae-Seong KIM
;
Kwang-Kuk KIM
;
Byoung Joon KIM
;
Jin Myoung SEOK
;
Jung-Joon SUNG
;
Tai-Seung NAM
;
Young-Eun PARK
;
Jin-Sung PARK
;
Sook Za KIM
;
Young-Chul CHOI
Author Information
- Publication Type:Original Article
- From:Journal of the Korean Neurological Association 2021;39(2):75-81
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Background:Pompe disease is a rare autosomal recessive disorder caused by the deficiency of a lysosomal enzyme, acid alpha-glucosidase (GAA). Early diagnosis and initiation of treatment with enzyme replacement therapy have remarkable effects on the prognosis of Pompe disease. We performed the expanded screening for late onset Pompe disease (LOPD) at eight centers in Korea.
Methods:From September 1, 2015, GAA activity were measured from both dried blood spot (DBS) and mixed leukocyte for 188 available patients. For 12 patients with low GAA activity, we performed Sanger sequencing of GAA gene.
Results:Among 188 patients, 115 were males. The mean of age of symptom onset and diagnosis were 34.3 years and 41.6 years. Among 12 patients with decreased GAA activity, two patients were confirmed to have LOPD with genetic test (c.1316T>A [p.M439K] + c.2015G>A [p.R672Q], c.1857C>G [p.S619R] + c.546G>C [leaky splicing]). Other two patients had homozygous G576S and E689K mutation, known as pseudodeficiency allele.
Conclusions:This study is expanded study of LOPD screening for targeted Korean population. We found two patients with LOPD, and the detection rate of LOPD is 1.06%. With application of modified GAA cutoff value (0.4), which was previously reported, there were no false positive results of GAA activity test using DBS. Therefore, it could be an appropriate screening test for LOPD in especially East-Asian population, in which pseudodeficiency allele is frequent.
